# Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

> **NCT02055976** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 218 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Bococizumab (PF-04950615;RN316)
- **DRUG:** Bococizumab (PF-04950615;RN316)
- **DRUG:** Bococizumab (PF-04950615;RN316)
- **DRUG:** Placebo
- **DRUG:** Ezetimibe
- **DRUG:** Bococizumab (PF-04950615;RN316)
- **DRUG:** Bococizumab (PF-04950615;RN316)
- **DRUG:** Bococizumab (PF-04950615;RN316)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02055976
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055976, "Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02055976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*